Subscribe to Print Edition | Thu., January 01, 2009 Tevet 5, 5769 | | Israel Time: 02:31 (EST+7)
Haaretz israel news English
web haaretz.com
Haaretz Toolbar
Diplomacy
Defense Jewish World Opinion National
Print Edition
Car Rental
Books Haaretz Magazine Business Real Estate Joy of Giving Travel Week's End Anglo File
Last update - 00:00 18/07/2008
Teva to buy U.S. drug giant for $7.5B in biggest ever purchase by Israeli company
By Yoram Gabison, TheMarker Correspondent, and The Associated Press
Tags: Barr, Teva

Teva Pharmaceuticals officially announced on Friday its plan to purchase U.S. generic drugmaker Barr Pharmaceuticals for $7.5 billion. If completed it would be the biggest deal ever by an Israeli company. The price is 44% above Barr's market value.

Teva Pharmaceutical Industries Ltd. also is offering to assume $1.5 billion of Montvale, New Jersey-based Barr Pharmaceuticals Inc.'s debt.

Barr shareholders will receive $39.90 in cash and 0.6272 of a Teva American Depositary Receipt for each share they own, or a total purchase price of $66.50 per share. That represents a 16 percent premium to Barr's $57.17 closing price Thursday.
Advertisement
Barr shares finished at $46.82 Wednesday, before reports that a deal was in the works sent the stock climbing 22 percent.

Already the largest generic drug maker in the world, Teva reported $9.4 billion in sales in 2007. Barr posted $2.5 billion in revenue, and the company describes itself as the largest maker of oral contraceptives in the U.S. It began selling a generic version of Bayer AG's birth-control pill Yasmin in the U.S. in July.

Barr also has the rights to sell a generic version of the attention deficit hyperactivity disorder drug Adderall XR starting April 1, 2009.

The deal will give Teva a larger presence in Central and Eastern Europe, where Barr already has a footprint because of its 2006 purchase of Pliva, a Croatian drug maker.

Based on Barr's 108.1 million shares outstanding at April 28, the deal is valued at $7.19 billion before assumed debt. In a statement, the companies valued the deal at $7.46 billion before debt.

Teva CEO Shlomo Yannai declared six months ago that Teva would increase its U.S. market share from 20% to 30% by 2012.

The greatest advantage for Teva of the deal, which was first revealed on Wednesday on the Web site of TheMarker, would be in increasing its lead over Sandoz. Teva is the world's largest generic drug manufacturer. Sandoz, the generic subsidiary of Novartis, is number two.

Barr's product line of branded drugs would give Teva a much greater presence in Eastern and Central Europe. Its ethical drug lines from its Duramed subsidiary would also add to Teva's share of the birth control market. Barr has a big advantage over Teva there, with such drugs as its Seasonique contraceptive pill and the morning-after pill Plan B. Altogether Barr sells 25 different types of oral contraceptives.

Barr's Enjuvia hormonal treatment for menopause would also be a nice addition to the Teva medicine chest.

Another benefit for Teva is Barr's access to the Russian market as well as to Poland and to Croatia, where Barr has a 37% market share. Barr purchased its Croatian subsidiary, PLIVA, in October 2006 for $2.5 billion. That company operates throughout Eastern and Central Europe.

Barr's chairman and CEO is Bruce Downey. Barr Pharmaceuticals is actually a holding company, operating through subsidiaries such as Barr Laboratories, Duramed and PLIVA.

Barr's present market value is $5.2 billion. It sells in 30 countries and develops both ethical and generic drugs. It had net profits of $23 million on sales of $608 million in the first quarter of 2008, up from profits of $12 million and sales of $597 million in the previous quarter, the last of 2007.

Its EBITDA - earnings before interest, taxes, depreciation and amortization - for the first quarter of the year was $153 million. It has 8,900 employees around the globe. The headquarters of the holding company is in New York, and Barr Labs is located in New Jersey.

Despite its strength in Central and Eastern Europe, its sales are still concentrated in the U.S., with 71% of its sales there.

In terms of the product mix, birth control pills made up 31% of revenues, while anti-psychotic drugs brought in 11% of sales with an additional 11% coming from pharmaceutical therapies for cardiac disease.

Ethical drugs made up 19% of Barr's sales, though the gross profit margins on those drugs reached 68%.

Barr was trading at a price to earnings ratio of 16.9, which means the sale price would reflect a P/E ratio of 24.

Teva is expected to pay for the deal with a mixture of shares and cash, as it did in the Ivax merger in 2006.

Teva sells 331 generic drugs in the U.S. and Barr would add another 150, compared to a total of 200 sold by Sandoz. Number three is Mylan, with a list of 170 drugs, followed by Barr in fourth place.

As of the end of the first quarter of 2008, Barr was waiting for approval of an additional 70 generic drugs with a combined existing market worth $30 billion in sales a year.

An ongoing romance

All told, the purchase would make it much easier for Teva to meet its 2009 goals.

Barr also develops bio-generic drugs, a market that is expected to grow strongly in coming years as patents expire. Barr also manufacturers injected drugs, a field Teva moved into in 2003 with its purchase of Sicor.

Teva and Barr have been cooperating since September 2005, when they signed an agreement to market Fexofenaine, a generic version of Allegra-D for the treatment of seasonal allergies and chronic skin diseases. The two have also cooperated on other generic drugs.

The joint projects with Teva have given both companies a good chance to appreciate each other's strengths and opportunities and has made it natural for Teva to think about the next step
Bookmark to del.icio.us  
 
Israelis targeted abroad
Gunman opens fire on Israelis working at shopping mall in Denmark.
Iran silences dissent
Newspaper forcibly shut down after article blaming Hamas for Gaza violence.
  1.   Teva-Barr 17:37  |  yigal koltin 18/07/08
  2.   Hyenas 10:21  |  Clickfool 19/07/08
 Read & React
Gideon Levy: Are Israel's pilots callous and blind to Gaza's suffering?
Responses: 308
Iran Jews stage pro-Palestinian rally near UN offices in Tehran
Responses: 119
Israel decides to push on with Gaza op until 'all goals reached'
Responses: 66
Gaza rocket strikes school in Be'er Sheva
Responses: 91
ANALYSIS / Hamas winning battle of public opinion in Arab world
Responses: 46
ANALYSIS / Rivalry among Israel's leaders at root of row on Gaza cease-fire
Responses: 28


More Headlines
23:32 IAF bombs Gaza mosque being used as weapons storehouse
02:13 Haniyeh: Palestinian victory in Gaza is near
23:18 Israel decides to push on with Gaza op until 'all goals reached'
13:27 Get up to the minute coverage of the warfare in Gaza directly to your email
23:16 4 rockets hit south as 'special situation' status extended to 40 kilometers from Gaza border
00:26 U.S. counterterror expert: Hamas has adopted Hezbollah-like tactics in Gaza
20:39 Gunman opens fire on Israelis working at mall in Denmark
21:05 WATCH: YouTube pulls some IDF videos showing Gaza assault
19:51 IN PICTURES / Israel battles Hamas in Gaza: Day five
18:56 GIDEON LEVY / The IAF, bullies of the clear blue skies
19:15 White House: Hamas must cease rocket fire as first step to truce
22:34 Livni: We will not allow thugs to rule the Middle East
18:26 Report: Iranian newspaper closed over article sympathetic to Israel
19:23 JEWISH WORLD / Pro-Israel camp would be wise to heed Muslim cries for peace
12:05 ANALYSIS / Rivalry among Israel's leaders at root of row on Gaza cease-fire
16:55 Protests abound at T.A. and Haifa Universities; Be'er Sheva students flee Gaza rockets in droves
19:14 Shin Bet: Hamas has been hit by IAF's Gaza offensive like never before
21:02 Turkey, Syria call on Islamic nations to pressure Israel to end Gaza offensive
09:26 ANALYSIS / Hamas racks up its first diplomatic victory in Gaza campaign
Previous Editions
Special Offers
Advertisement
Summer in Israel
Israeli style - Tzofim Chetz V'Keshet 2009
The Caesarea Golf Residence.
The Right Place.
You can make a direct IMPACT!
on the life of an Israeli soldier
State of Israel Bonds
During this time of market volatility, Israel bonds can help.
SURF RAMBAM
Keep current about new-wave medical care, education and research.
Summer Camp in Israel
The best place for your children this summer
Academic Studies in Israel
All the Q & A at the IDC HERZLIYA Open House, January 9,2009
Fattal Hotel Chain
Perfectly located hotels on best resorts of Israel.
Car rental in Israel
Shlomo Sixt Receive $15.00 from our low rates.
Eldan Rent a Car
Israel's leading car rental company offers you a 20% discount on all online reservations
Jewish Singles Personal Ads
Find the love of your life on JDate.com
Hebrew Summer courses
From $39.95
Junkyard
Junk a car - get free towing nationwide and a tax-deductible receipt
Home | TV | Print Edition | Diplomacy | Opinion | Arts & Leisure | Sports | Jewish World | Underground | Site rules |
Real Estate in Israel | Travel to Israel with Haaretz | Hotels Israel | Restaurants Israel | Tourist attractions Israel | Shops Israel
birthright Israel | Search engine marketing
Haaretz.com, the online edition of Haaretz Newspaper in Israel, offers real-time breaking news, opinions and analysis from Israel and the Middle East. Haaretz.com provides extensive and in-depth coverage of Israel, the Jewish World and the Middle East, including defense, diplomacy, the Arab-Israeli conflict, the peace process, Israeli politics, Jerusalem affairs, international relations, Iran, Iraq, Syria, Lebanon, the Palestinian Authority, the West Bank and the Gaza Strip, the Israeli business world and Jewish life in Israel and the Diaspora.
© Copyright  Haaretz. All rights reserved